Senate Special Committee on Aging Examines Drug Pricing

March 17, 2016
Contact: Ben Jenkins
Email: [email protected]

Senate Special Committee on Aging Examines Drug Pricing

Ahead of this morning's Senate Special Committee on Aging hearing on drug pricing, John Rother, executive director of the Campaign for Sustainable Rx Pricing issued the following statement:

"Today's hearing shows that fighting high prescription drug prices is truly a bipartisan battle. Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It's unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice."

And, the problem of rising prescription drug prices is even more widespread than just Turing Pharmaceuticals or a few bad actors. Learn more about the startling pace of across-the-board price increases here in our fact sheet.

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.